CollPlant Biotechnologies Ltd.

NasdaqGM:CLGN Stock Report

Market Cap: US$64.2m

CollPlant Biotechnologies Future Growth

Future criteria checks 2/6

CollPlant Biotechnologies is forecast to grow earnings and revenue by 57.6% and 28.5% per annum respectively while EPS is expected to grow by 56.2% per annum.

Key information

57.6%

Earnings growth rate

56.2%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate28.5%
Future return on equityn/a
Analyst coverage

Low

Last updated30 May 2024

Recent future growth updates

Recent updates

We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Feb 03
We're Interested To See How CollPlant Biotechnologies (NASDAQ:CLGN) Uses Its Cash Hoard To Grow

Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

Nov 02
Is CollPlant Biotechnologies (NASDAQ:CLGN) In A Good Position To Deliver On Growth Plans?

CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Sep 06
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Shares Lagging The Industry But So Is The Business

Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Jul 14
Here's Why We're Watching CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Mar 02
Here's Why We're Not Too Worried About CollPlant Biotechnologies' (NASDAQ:CLGN) Cash Burn Situation

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

Nov 10
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Are In A Position To Invest In Growth

CollPlant Non-GAAP EPS of -$0.36, revenue of $0.07M

Aug 25

We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

Jul 22
We Think CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Drive Business Growth

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 22
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CollPlant Biotechnologies - A Cheap, Game-Changing Bio-Printing Platform Company

Aug 05

Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

Jul 29
Why We Think Shareholders May Be Considering Bumping Up CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) CEO Compensation

The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Jun 09
The Strong Earnings Posted By CollPlant Biotechnologies (NASDAQ:CLGN) Are A Good Indication Of The Strength Of The Business

Earnings and Revenue Growth Forecasts

NasdaqGM:CLGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026220N/AN/A1
12/31/202515-6N/AN/A1
12/31/20243-17N/AN/A1
12/31/202311-7-4-3N/A
9/30/202311-7-5-4N/A
6/30/202311-7-15-14N/A
3/31/20231-17-15-14N/A
12/31/20220-17-15-14N/A
9/30/20221-16-14-13N/A
6/30/20221-15-14-12N/A
3/31/20221-14-14-12N/A
12/31/202116013N/A
9/30/202116123N/A
6/30/202120578N/A
3/31/202120699N/A
12/31/20206-6-5-4N/A
9/30/20206-7-5-4N/A
6/30/20203-11-8-7N/A
3/31/20202-11-8-7N/A
12/31/20192-11-7-6N/A
9/30/20196-6-2-1N/A
6/30/20196-6-2-1N/A
3/31/20195-4-2-1N/A
12/31/20185-6-2-1N/A
9/30/20181-6-7-6N/A
6/30/20181-6-6-6N/A
3/31/20181-7-5-5N/A
12/31/20170-6-5-5N/A
9/30/20170-6N/A-5N/A
6/30/20170-7N/A-5N/A
3/31/20170-7N/A-5N/A
12/31/20160-7N/A-5N/A
9/30/20160-7N/A-5N/A
6/30/2016N/A-7N/A-5N/A
3/31/2016N/A-6N/A-5N/A
12/31/2015N/A-5N/A-4N/A
9/30/2015N/A-4N/A-4N/A
6/30/2015N/A-4N/A-4N/A
3/31/2015N/A-3N/A-3N/A
12/31/2014N/A-3N/A-3N/A
9/30/2014N/A-4N/A-4N/A
6/30/2014N/A-4N/A-4N/A
3/31/2014N/A-4N/A-4N/A
12/31/2013N/A-5N/A-4N/A
9/30/2013N/A-5N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLGN's revenue (28.5% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CLGN's revenue (28.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.